Suggested remit: To appraise the clinical and cost effectiveness of nivolumab with chemotherapy and nivolumab monotherapy within its marketing authorisation for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer (NSCLC).
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6310

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 May 2024 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.  In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. 
16 January 2024 - 13 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6310
15 September 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-April 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-June 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
03 July 2023 In progress
23 November 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual